The Myonex Advantage

Myonex understands that clinical trials are complex, ever-changing, and expensive. “One size fits all” solutions don’t work. Over 30 years, we’ve built a comprehensive suite of sourcing and supply services to address this reality with dedicated teams to serve your trial’s specific needs.

MYONEX’S SERVICES WORK HARMONIOUSLY TOGETHER FOR YOUR GLOBAL TRIAL TO:

improve
efficiency

increase
effectiveness

create
flexibility

reduce
waste

We have the flexibility to create solutions for your trial’s unique needs and challenges. Myonex is your trusted clinical trial supply partner.

Global Distribution Network

Our expansive partner depot network supports clinical trial distribution to over 70 countries.

The Myonex network includes:

  • facilities in the U.S., the United Kingdom, and Denmark
  • distribution hubs in Germany and Singapore
  • a strategic partner depot network spanning countries in Europe, North America, Latin America, Asia Pacific, Middle East, and Africa

With Myonex as your clinical trial supply partner, you’ll gain…

  • expert problem-solving and tailored solutions for any challenge
  • speedy access to the right supply of drugs so the trial can start on time
  • tools for reducing overage to eliminate waste
  • flexibility to change drug supply requests
  • ways to reduce costs
  • answers to your inquiries

Experience the simplicity of working with a single vendor who can handle:

  • comparator drug sourcing and supply
  • packaging and distribution
  • returning or redistributing unused drugs
  • providing all equipment and supplies needed for the trial, from IVs and tubing to refrigeration — and everything in between.

Let’s discuss how we can help you plan your next global clinical trial.

Go to article: Home | Antibiotic AdjacentGo to article: In this issueGo to article: ContentsGo to article: SHL Company InsightGo to article: SHL MedicalGo to article: TiveGo to article: Controlant Company InsightGo to article: ControlantGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: L.B. Bohle MaschinenGo to article: L.B Bohle Company InsightGo to article: ACG WorldwideGo to article: CommentGo to article: HPV infections drop due to widespread vaccinationGo to article: Europe reports the highest prevalence of chronic cough across the 7MMGo to article: How could vaccine hesitancy affect the prevalence of hearing disorders?Go to article: Datwyler Company Insight Go to article: DatwylerGo to article: RegPakGo to article: PfeifferGo to article: In DepthGo to article: Antibiotic adjacent: the alternatives tackling AMR Go to article: Regenerative medicine: ready for the big leagues? Go to article: Human challenge trials: pandemic exit strategy or ethical nightmare?Go to article: Drug dispensing goes digitalGo to article: Could this Novartis initiative finally cure sickle cell disease?Go to article: Centessa Pharmaceuticals: forging a new path for pharma R&DGo to article: Biomax Company InsightGo to article: BiomaxGo to article: DuojectGo to article: Duoject Company InsightGo to article: In DataGo to article: Deals analysisGo to article: The pharma industry key listGo to article: Global markets and indicesGo to article: Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: The Solubility Company - Company Insight Go to article: The Solubility companyGo to article: MyonexGo to article: BaxterGo to article: EventsGo to article: Next issue